DEKA Biosciences
Deka Biosciences is an innovative biotechnology company focused on developing targeted cytokine therapies for cancer and inflammatory diseases. Their platform, Diakine™, utilizes paired cytokines and advanced targeting systems to enhance immune response and reduce toxicity. The company emphasizes personalized medicine, leveraging genetic and biomarker insights to tailor treatments. Led by a team of experienced industry veterans and supported by a scientific advisory board comprising global experts, Deka is committed to advancing clinical trials and expanding its pipeline of cytokine-based therapeutics.
Industries
Nr. of Employees
small (1-50)
DEKA Biosciences
Germantown, Maryland, United States, North America
Products
EGFR‑directed multi‑cytokine fusion therapeutic (early clinical)
A targeted single‑chain multi‑cytokine fusion therapeutic in first‑in‑human Phase I evaluation for EGFR‑expressing solid tumors; combines stimulatory and anti‑inflammatory cytokine domains with a targeting scFv to enhance tumor localization and modulate systemic immune activation.
Tissue‑directed anti‑inflammatory multi‑cytokine therapeutic (preclinical)
Preclinical constructs combining multiple anti‑inflammatory cytokine domains with scFv‑based targeting to enrich inflamed tissues for localized treatment of autoimmune and inflammatory diseases (examples include gastrointestinal, dermatologic, and rheumatologic indications).
EGFR‑directed multi‑cytokine fusion therapeutic (early clinical)
A targeted single‑chain multi‑cytokine fusion therapeutic in first‑in‑human Phase I evaluation for EGFR‑expressing solid tumors; combines stimulatory and anti‑inflammatory cytokine domains with a targeting scFv to enhance tumor localization and modulate systemic immune activation.
Tissue‑directed anti‑inflammatory multi‑cytokine therapeutic (preclinical)
Preclinical constructs combining multiple anti‑inflammatory cytokine domains with scFv‑based targeting to enrich inflamed tissues for localized treatment of autoimmune and inflammatory diseases (examples include gastrointestinal, dermatologic, and rheumatologic indications).
Services
Collaborative therapeutic development partnerships
Co‑development, licensing and external collaboration to advance targeted multi‑cytokine fusion therapeutics and companion diagnostic assays.
Collaborative therapeutic development partnerships
Co‑development, licensing and external collaboration to advance targeted multi‑cytokine fusion therapeutics and companion diagnostic assays.
Expertise Areas
- Immuno‑oncology drug discovery
- Inflammation and autoimmune therapeutic development
- Protein engineering and fusion biologic design
- Biomarker‑driven precision medicine
Key Technologies
- Single‑chain multi‑cytokine fusion proteins
- Affinity‑modified cytokine variants
- Low‑affinity cytokine engineering
- scFv targeting scaffolds